Lymphoma Canada is preparing submissions for the pan-Canadian Oncology Drug Review (pCODR) for two upcoming drug reviews for PTCL:
1. Pralatrexate (Folotyn) for relapsed or refractory PTCL
2. Belinostat (Beleodaq) for relapsed or refractory PTCL
If you have or had Peripheral T-Cell Lymphoma (PTCL), you can help by completing our survey.
The survey provides us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, June 8th, and should only take 15 minutes of your time.
You may access the survey by clicking the appropriate link below.
Survey for those WITH pralatrexate (Folotyn) OR belinostat (Beleodaq) Experience
PTCL Patient Survey for those WITHOUT pralatrexate OR belinostat Experience
Please share and help us spread the word.
Thank you for your support.
